-
Published05/08/2026
-
Today13/09/2026
-
Deadline31/07/2028
-
Opening of tenders31/07/2028
Utilities
- indicates text translated automatically in your browsing language
Medicines containing the active substance golimumab (ATC: L04AB06)
The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V for finished medicinal products with the active substance golimumab (ATC: L04AB06) as part of an open-house model. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement pursuant to § 130a(8) SGB V on the above-mentioned active substances or medicinal products. Interested pharmaceutical companies can request the participation documents and the respective contract from the aforementioned contact address. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company completes and signs the requested participation documents in full.
sen-info
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.